Collaboration versus outsourcing: the need to think outside the box.

Abstract:

:As has been widely reviewed elsewhere, the pharmaceutical industry is experiencing an 'innovation deficit' as evidenced by the decline in new chemical entity output. This decline, compounded by increased costs and regulatory requirements highlights the need to significantly revise strategic options across the drug-discovery spectrum. Within such revision(s), much of the focus has been on outsourcing to reduce, or at least contain, costs, but if the underlying predominance of 'closed collaborations' is not challenged to allow better use of combined knowledge and, thus, move towards a more genuine collaborative process then a 'numbers only' approach will not bring medium-to-long-term survival. There are many problems to confront in evolving new sustainable strategies, a real need to think differently exists and should to be cultivated. This article reviews current outsourcing and collaboration strategies to provide a perspective on how great knowledge sharing could help revise the drug-discovery process.

journal_name

Future Med Chem

authors

Robertson GM,Mayr LM

doi

10.4155/fmc.11.160

subject

Has Abstract

pub_date

2011-12-01 00:00:00

pages

1995-2020

issue

16

eissn

1756-8919

issn

1756-8927

journal_volume

3

pub_type

杂志文章,评审
  • Fluorine in medicinal chemistry: a century of progress and a 60-year retrospective of selected highlights.

    abstract::This perspective explores the origins of both fluorine and medicinal chemistry a century ago and traces the early history of the intersection of these areas and the subsequent roles that fluorine has played in advancing medicinal innovations and diagnoses during the past 60 years. The overview highlights remarkable br...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc.09.65

    authors: Filler R,Saha R

    更新日期:2009-08-01 00:00:00

  • Computer tools in the discovery of HIV-1 integrase inhibitors.

    abstract::Computer-aided drug design (CADD) methodologies have made great advances and contributed significantly to the discovery and/or optimization of many clinically used drugs in recent years. CADD tools have likewise been applied to the discovery of inhibitors of HIV-1 integrase, a difficult and worthwhile target for the d...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc.10.193

    authors: Liao C,Nicklaus MC

    更新日期:2010-07-01 00:00:00

  • Insights on how the Mycobacterium tuberculosis heme uptake pathway can be used as a drug target.

    abstract::Mycobacterium tuberculosis (Mtb) acquires non-heme iron through salicylate-derived siderophores termed mycobactins whereas heme iron is obtained through a cascade of heme uptake proteins. Three proteins are proposed to mediate Mtb heme iron uptake, a secreted heme transporter (Rv0203), and MmpL3 and MmpL11, which are ...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc.13.109

    authors: Owens CP,Chim N,Goulding CW

    更新日期:2013-08-01 00:00:00

  • Anti-inflammatory indomethacin analogs endowed with preferential COX-2 inhibitory activity.

    abstract:AIM:The undeniable indomethacin potency has always suffered serious obstacles such as gastric damage. Continuous attempts to develop potent yet safe indomethacin analogs have never ceased. RESULTS:Herein are new indole derivatives 4a-h and 5a-c, which were synthesized via Fisher indole reaction, evaluated for both the...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc-2018-0224

    authors: Amin NH,El-Saadi MT,Hefny AA,Abdelazeem AH,Elshemy HA,Abdellatif KR

    更新日期:2018-12-06 00:00:00

  • Natural products and ion channel pharmacology.

    abstract::An accelerated rate of natural-product discovery is critical for the future of ion channel pharmacology. For the full potential of natural products to be realized, an interdisciplinary initiative is required that combines chemical ecology and ion channel physiology. A prime source of future drug leads targeted to ion ...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc.10.31

    authors: Teichert RW,Olivera BM

    更新日期:2010-05-01 00:00:00

  • Fatty acid and mineral receptors as drug targets for gastrointestinal disorders.

    abstract::Nutrient-sensing receptors, including fatty acid receptors (FFA1-FFA4), Ca2+-sensing receptors and Zn2+-sensing receptors, are involved in several biological processes. These receptors are abundantly expressed in the GI tract, where they have been shown to play crucial roles in regulating GI function. This review prov...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc-2016-0205

    authors: Pongkorpsakol P,Moonwiriyakit A,Muanprasat C

    更新日期:2017-03-01 00:00:00

  • Interview with Chi-Chao Chan. Interview by Isaac Bruce.

    abstract::Chi-Chao Chan, an American board certified ophthalmologist, is the Chief of Immunopathology Section, Laboratory of Immunology and the Head of Histology Core at the National Eye Institute at National Institutes of Health (USA). In 1967, Dr Chan graduated from Chungzhan Medical College in Guangzhou, China and then earne...

    journal_title:Future medicinal chemistry

    pub_type: 历史文章,面试

    doi:10.4155/fmc.12.171

    authors: Chan CC

    更新日期:2012-11-01 00:00:00

  • Pseudomonas aeruginosa: targeting cell-wall metabolism for new antibacterial discovery and development.

    abstract::Pseudomonas aeruginosa is a leading cause of hospital-acquired infections and is resistant to most antibiotics. With therapeutic options against P. aeruginosa dwindling, and the lack of new antibiotics in advanced developmental stages, strategies for preserving the effectiveness of current antibiotics are urgently req...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc-2016-0017

    authors: Lamers RP,Burrows LL

    更新日期:2016-06-01 00:00:00

  • Novel neuraminidase inhibitors: identification, biological evaluation and investigations of the binding mode.

    abstract:BACKGROUND:The pathogenicity of influenza A and B viruses depends on the function of influenza neuraminidase (NA). Emerging resistant influenza A viruses of subtype H1N1 increasingly challenge the effectiveness of established NA inhibitors. Recent computational studies have indicated several weak points of NA that can ...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc.10.292

    authors: Kirchmair J,Rollinger JM,Liedl KR,Seidel N,Krumbholz A,Schmidtke M

    更新日期:2011-03-01 00:00:00

  • Sialic acid as a target for the development of novel antiangiogenic strategies.

    abstract::Sialic acid is associated with glycoproteins and gangliosides of eukaryotic cells. It regulates various molecular interactions, being implicated in inflammation and cancer, where its expression is regulated by sialyltransferases and sialidases. Angiogenesis, the formation of new capillaries, takes place during inflamm...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc-2018-0298

    authors: Chiodelli P,Urbinati C,Paiardi G,Monti E,Rusnati M

    更新日期:2018-12-01 00:00:00

  • Drugging the schistosome zinc-dependent HDACs: current progress and future perspectives.

    abstract::Schistosomes, like many eukaryotic pathogens, typically display morphologically distinct stages during their life cycles. Epigenetic mechanisms underlie the pathogens' morphological transformations, and the targeting of epigenetics-driven cellular programs therefore represents an Achilles' heel of parasites. To speed ...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc.15.25

    authors: Marek M,Oliveira G,Pierce RJ,Jung M,Sippl W,Romier C

    更新日期:2015-01-01 00:00:00

  • The critical role of epigallocatechin gallate in regulating mitochondrial metabolism.

    abstract::Epigallocatechin gallate (EGCG), one of polyphenols isolated from green tea, exhibits biology-benefiting effects with minimum severe adverse. EGCG is known to be a mitochondrion-targeting medicinal agent, regulating mitochondrial metabolism, including mitochondrial biogenesis, mitochondrial bioenergetics, and mitochon...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc-2017-0204

    authors: Shi W,Li L,Ding Y,Yang K,Chen Z,Fan X,Jiang S,Guan Y,Liu Z,Xu D,Wu L

    更新日期:2018-04-01 00:00:00

  • An overview of bacterial efflux pumps and computational approaches to study efflux pump inhibitors.

    abstract::Micro-organisms express a wide range of transmembrane pumps known as multidrug efflux pumps that improve the micro-organism's ability to survive in severe environments and contribute to resistance against antibiotic and antimicrobial agents. There is significant interest in developing efflux inhibitors as an adjunct t...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc.15.173

    authors: Jamshidi S,Sutton JM,Rahman KM

    更新日期:2016-01-01 00:00:00

  • Linolenic acid-modified MPEG-PEI micelles for encapsulation of amphotericin B.

    abstract::Aim: To encapsulate amphotericin B (AmB) with reduced toxicity and comparable activity. Results & methodology: The α-linolenic acid (ALA)-modified monomethoxy polyethylene glycol-g-PEI-g-ALA conjugate was employed to prepare AmB-loaded micelles (AmB-M). In vitro activity and release behavior of AmB-M were investigated...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc-2018-0580

    authors: Xu H,Teng F,Zhou F,Zhu L,Wen Y,Feng R,Song Z

    更新日期:2019-10-01 00:00:00

  • Ovarian cancer cells cisplatin sensitization agents selected by mass cytometry target ABCC2 inhibition.

    abstract:AIM:Cisplatin resistance in ovarian cancer remains a complex problem as tumors frequently develop resistance against drugs, a mechanism sometimes mediated by ATP-Binding Cassette transporters. Our goal was to find compounds restricting their inhibition capacity to the cisplatin efflux mediated by ABCC2 pump, among prev...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc-2017-0308

    authors: Comsa E,Nguyen KA,Loghin F,Boumendjel A,Peuchmaur M,Andrieu T,Falson P

    更新日期:2018-06-01 00:00:00

  • Recent developments and advances of FGFR as a potential target in cancer.

    abstract::FGFs and their receptors (FGFRs) are critical for many biologic processes, including angiogenesis, wound healing and tissue regeneration. Aberrations in FGFR signaling are common in cancer, making FGFRs a promising target in antitumor studies. To date, many FGFR inhibitors are being detected in clinical studies, and r...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc-2018-0103

    authors: Xue WJ,Li MT,Chen L,Sun LP,Li YY

    更新日期:2018-09-01 00:00:00

  • Cyclin-dependent kinase 7 inhibitors in cancer therapy.

    abstract::Cyclin-dependent kinase 7 (CDK7) plays crucial roles in the regulation of cell cycle and transcription that are tightly associated with cancer development and metastasis. The recent identification of the first covalent inhibitor which possesses high specificity against CDK7 prompts intense studies on designing highly ...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc-2019-0334

    authors: Wang M,Wang T,Zhang X,Wu X,Jiang S

    更新日期:2020-05-01 00:00:00

  • Development and strategies of VEGFR-2/KDR inhibitors.

    abstract::VEGF is an important signaling protein involved in both vasculogenesis and angiogenesis. As an essential receptor protein tyrosine kinase propagating cellular signal transduction processes, VEGFR-2 is a central target for drug discovery against tumor-associated angiogenesis. Since the autophosphorylation of VEGFR-2 re...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc.12.121

    authors: Huang L,Huang Z,Bai Z,Xie R,Sun L,Lin K

    更新日期:2012-09-01 00:00:00

  • Dual-pharmacology muscarinic antagonist and β₂ agonist molecules for the treatment of chronic obstructive pulmonary disease.

    abstract::Chronic obstructive pulmonary disease (COPD) is one of the leading causes of death in the world today. Bronchodilators, particularly muscarinic antagonists and β(2) agonists, are recommended for patients with moderate to severe COPD. Dual-pharmacology muscarinic antagonist- β(2) agonist (MABA) molecules present an exc...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc.11.106

    authors: Hughes AD,Jones LH

    更新日期:2011-10-01 00:00:00

  • Purine homo-N-nucleoside+coumarin hybrids as pleiotropic agents for the potential treatment of Alzheimer's disease.

    abstract:AIM:Due to the complex nature of Alzheimer's disease, there is a renewed search for pleiotropic agents. RESULTS:Purine+coumarin hybrids have been synthesized and tested for the potential treatment of Alzheimer's disease. Hybrids 6, 4a-b, 14c and 14e inhibit significantly soybean lipoxygenase, whereas derivatives 14b, ...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc.14.158

    authors: Kallitsakis MG,Yañez M,Soriano E,Marco-Contelles J,Hadjipavlou-Litina DJ,Litinas KE

    更新日期:2015-01-01 00:00:00

  • Dynorphin A analogs for the treatment of chronic neuropathic pain.

    abstract::Chronic pain is one of the most ubiquitous diseases in the world, but treatment is difficult with conventional methods, due to undesirable side effects of treatments and unknown mechanisms of pathological pain states. The endogenous peptide, dynorphin A has long been established as a target for the treatment of pain. ...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc.15.164

    authors: Hall SM,Lee YS,Hruby VJ

    更新日期:2016-01-01 00:00:00

  • Rho kinase as a target for cerebral vascular disorders.

    abstract::The development of novel pharmaceutical treatments for disorders of the cerebral vasculature is a serious unmet medical need. These vascular disorders are typified by a disruption in the delicate Rho signaling equilibrium within the blood vessel wall. In particular, Rho kinase overactivation in the smooth muscle and e...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc.15.45

    authors: Bond LM,Sellers JR,McKerracher L

    更新日期:2015-01-01 00:00:00

  • Benford's law in medicinal chemistry: Implications for drug design.

    abstract::Aim: The explosion of data based technology has accelerated pattern mining. However, it is clear that quality and bias of data impacts all machine learning and modeling. Results & methodology: A technique is presented for using the distribution of first significant digits of medicinal chemistry features: logP, logS, a...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc-2019-0006

    authors: García-Sosa AT

    更新日期:2019-09-01 00:00:00

  • Structure-activity relationship of natural and synthetic coumarin derivatives against Mycobacterium tuberculosis.

    abstract::Aim: Eight coumarin derivatives (1a-h) obtained from natural (-)-mammea A/BB (1) and 13 synthetic coumarins (2-14) had their cytotoxicity and biological activity evaluated against Mycobacterium tuberculosis H37Rv reference strain and multidrug-resistant clinical isolates. Materials & methods: Anti-M. tuberculosis acti...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc-2018-0281

    authors: Pires CT,Scodro RB,Cortez DA,Brenzan MA,Siqueira VL,Caleffi-Ferracioli KR,Vieira LC,Monteiro JL,Corrêa AG,Cardoso RF

    更新日期:2020-09-01 00:00:00

  • N3-substituted thymidine bioconjugates for cancer therapy and imaging.

    abstract::The compound class of 3-carboranyl thymidine analogues (3CTAs) are boron delivery agents for boron neutron capture therapy (BNCT), a binary treatment modality for cancer. Presumably, these compounds accumulate selectively in tumor cells via intracellular trapping, which is mediated by hTK1. Favorable in vivo biodistri...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc.13.31

    authors: Khalil A,Ishita K,Ali T,Tjarks W

    更新日期:2013-04-01 00:00:00

  • Advances in antibiotic drug discovery: reducing the barriers for antibiotic development.

    abstract::Antibiotic drug discovery has been an essential field of research since the early 1900s, but the threat from infectious bacteria has only increased over the decades because of the emergence of widespread multidrug resistance. In this review, we discuss the recent advances in natural product, computational and medicina...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc-2020-0247

    authors: Murphy KE,Sloan GF,Lawhern GV,Volk GE,Shumate JT,Wolfe AL

    更新日期:2020-11-01 00:00:00

  • Routes to drug design via bioisosterism of carboxyl and sulfonamide groups.

    abstract:AIM:The similarity in the biological function of the bioisosteric pair, carboxyl and sulfonamide functional groups, is studied using the quantitative tool, average electron density of the bioisosteric moiety in drug molecules and the qualitative tool, electrostatic potential. Results/methodology: Five different capping...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc-2017-0136

    authors: Arabi AA

    更新日期:2017-12-01 00:00:00

  • Nanoformulations for glioblastoma multiforme: a new hope for treatment.

    abstract::Glioblastoma multiforme (GBM) is the most common primary malignant brain tumor in adults, associated with a high mortality rate and a survival of between 12 and 15 months after diagnosis. Due to current treatment limitations involving surgery, radiotherapy and chemotherapy with temozolamide, there is a high rate of tr...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc-2018-0521

    authors: Ortiz R,Cabeza L,Perazzoli G,Jimenez-Lopez J,García-Pinel B,Melguizo C,Prados J

    更新日期:2019-09-01 00:00:00

  • Current and future perspectives on the chemotherapy of the parasitic protozoa Trichomonas vaginalis and Entamoeba histolytica.

    abstract::Trichomonas vaginalis and Entamoeba histolytica are clinically important protozoa that affect humans. T. vaginalis produces sexually transmitted infections and E. histolytica is the causative agent of amebic dysentery. Metronidazole, a compound first used to treat T. vaginalis in 1959, is still the main drug used worl...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc.09.59

    authors: Moya IA,Su Z,Honek JF

    更新日期:2009-07-01 00:00:00

  • Research progress of selective small molecule bromodomain-containing protein 9 inhibitors.

    abstract::The bromodomain proteins, known as the key targets in epigenetics, are 'readers' of acetylated lysine of histones. As a member of bromodomain proteins, bromodomain-containing protein 9 (BRD9) is a subunit of mammalian SWI/SNF chromatin remodeling complexes. However, the biological functions and the potential applicati...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc-2017-0243

    authors: Hui M,Jian Z,Peiyuan Z,Zhenwei W,Huibin Z

    更新日期:2018-04-01 00:00:00